Panbela Therapeutics logo
  • About Us
    • Company Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Overview of SBP-101
    • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Newsroom
    • Press Releases
    • Events & Presentations
  • Investor Relations
    • Corporate Governance
    • Financial Information
    • Annual Reports & Proxy Statements
    • Investor Contact Info
  • Contact

Annual Reports & Proxy Statements

  • Overview
  • Corporate Governance
  • Financial Information
  • Annual Reports & Proxy Statements
  • Investor Contact Information

Sun BioPharma 2019 Annual Report including 2020 Proxy Statement »
Sun BioPharma 2018 Annual Report including 2019 Proxy Statement »
Sun BioPharma 2017 Annual Report including 2018 Proxy Statement »
Sun BioPharma Notice of Consent Solicitation »
Sun BioPharma 2016 Annual Report including 2017 Proxy Statement »
Sun BioPharma 2015 Annual Report including 2016 Proxy Statement »

Quick Links

  • Home
  • About Us
  • Our Science
  • Newsroom
  • Investor Relations
  • Contact

Contact

bd@panbela.com
 
Sign up to receive press releases via email:

News & Events

Panbela Provides Business Update and Reports Q1 2021 Financial Results

Panbela Schedules Conference Call on May 12, 2021 to Report 2021 First Quarter Financial Results

Panbela Announces Partial Clinical Hold Lifted on Phase I Polyamine Metabolic Inhibitor Study in Pancreatic Cancer

Copyright ©2021 Panbela Therapeutics, Inc. All Rights Reserved.